ALLK (Allakos) Float Percentage Of Total Shares Outstanding : 73.67% (As of May. 06, 2025)

View and export this data going back to 2018. Start your Free Trial

What is Allakos Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Allakos's float shares is 66.58 Mil. Allakos's total shares outstanding is 90.38 Mil. Allakos's float percentage of total shares outstanding is 73.67%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Allakos's Insider Ownership is 2.82%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Allakos's Institutional Ownership is 82.89%.

Allakos Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Allakos's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	66.58	/	90.38
	=	73.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allakos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

37Z:Germany

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.

Executives

Harlan Baird Radford	officer: Chief Financial Officer	C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Amy L Ladd	director	INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson	officer: Chief Medical Officer	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald	officer: General Counsel and Secretary	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James	director	C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi	officer: COO, CFO and Secretary	ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander	director, officer: President and CEO	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rasmussen Henrik S Md	officer: Chief Medical Officer	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn	director, 10 percent owner	5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson	10 percent owner	701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067